top issues in the cannabis industry for 2026 bank 18

Top Issues in the Cannabis Industry for 2026: Banking, Hemp Redefinition, and Market Contraction

CED Clinical Relevance
#15 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
PolicyHempTHCIndustryCBD
Why This Matters
Popular hemp products like delta-8, THCA flower, and HHC will be reclassified as Schedule I controlled substances, meaning the products you currently buy legally could become federally illegal overnight.
Clinical Summary

Legal analysis lays out how the new hemp law converts the 2018 Farm Bill ‘patchwork loophole’ into a clear federal prohibition framework. Delta-8, delta-10, THCA flower, HHC, and THCP will all fall outside ‘hemp’ and be treated as Schedule I. Major banks remain on the sidelinesโ€”rescheduling to Schedule III doesn’t equal legalization. SAFER Banking Act remains the clearest path to banking reform. Market tightening expected well before Nov deadline.

Dr. Caplan’s Take
“Reclassifying compounds that millions use safely as Schedule I,the same category as heroin,reveals a prohibition framework masquerading as public health policy.”
Clinical Perspective

THE GREAT HEMP RECLASSIFICATION: What Actually Happens After November

Legal analyses are now spelling out the practical consequences of the Nov 2026 hemp ban in granular detail, and they’re sobering.

Delta-8, delta-10, THCA flower, HHC, and THCP will all fall outside the federal definition of hemp and be treated as Schedule I controlled substances. The 2018 Farm Bill’s delta-9-only loophole is being sealed. In its place: a total THC standard that captures every known intoxicating cannabinoid.

But the prohibition framework extends beyond the obvious targets. Legal experts note that the ‘similar effects’ standard gives federal agencies sweeping authority to add cannabinoids to the restricted list. If CBD or CBN are determined to have THC-like effects, they could be subject to the 0.4mg container limitโ€”potentially making large CBD tincture bottles non-compliant.

Meanwhile, major banks won’t follow rescheduling. Schedule III doesn’t equal legalization, and most financial institutions view cannabis proceeds as carrying significant compliance risk. The SAFER Banking Act remains the only realistic path to industry-wide banking reform.

The market is already tightening. Payment processors are reassessing risk. Retailers are demanding updated COAs. Insurance carriers are reviewing exclusions. The November deadline is nine months away, but the economic effects are arriving now.

๐Ÿ’ฌ Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan โ†’

Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’